Epigenetic Targets and Their Inhibitors in Thyroid Cancer Treatment

Although biologically targeted therapies based on key oncogenic mutations have made significant progress in the treatment of locally advanced or metastatic thyroid cancer, the challenges of drug resistance are urging us to explore other potentially effective targets. Herein, epigenetic modifications...

Full description

Saved in:
Bibliographic Details
Published inPharmaceuticals (Basel, Switzerland) Vol. 16; no. 4; p. 559
Main Authors Zhang, Ke, Wang, Junyao, He, Ziyan, Qiu, Xian, Sa, Ri, Chen, Libo
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.04.2023
MDPI
Subjects
Analysis
Cancer
Cancer therapies
Care and treatment
Chromatin
Development and progression
DNA methylation
Drug resistance
Drug therapy
Epigenetic inheritance
Epigenetics
Genetic aspects
Health aspects
inhibitor
Kinases
Lysine
Methylation
Methyltransferases
Review
RNA
target
Thyroid cancer
China
Serbia
thyroid cancer
inhibitor
epigenetics
target
Online AccessGet full text

Cover

More Information
Summary:Although biologically targeted therapies based on key oncogenic mutations have made significant progress in the treatment of locally advanced or metastatic thyroid cancer, the challenges of drug resistance are urging us to explore other potentially effective targets. Herein, epigenetic modifications in thyroid cancer, including DNA methylation, histone modifications, non-coding RNAs, chromatin remodeling and RNA alterations, are reviewed and epigenetic therapeutic agents for the treatment of thyroid cancer, such as DNMT (DNA methyltransferase) inhibitors, HDAC (histone deacetylase) inhibitors, BRD4 (bromodomain-containing protein 4) inhibitors, KDM1A (lysine demethylase 1A) inhibitors and EZH2 (enhancer of zeste homolog 2) inhibitors, are updated. We conclude that epigenetics is promising as a therapeutic target in thyroid cancer and further clinical trials are warranted.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1424-8247
1424-8247
DOI:10.3390/ph16040559